Intraocular lens
By setting bottom-hole-shaped drug-carrying holes and sustained-release holes at the edge of the optical part of the intraocular lens, the slow release of drugs is achieved, which solves the problems of comfort and stability of the intraocular lens, reduces postoperative inflammation and posterior capsule opacification, and improves the visual correction effect.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- YANTAI AIBO NORD MEDICAL MATERIALS CO LTD
- Filing Date
- 2025-08-20
- Publication Date
- 2026-08-04
AI Technical Summary
Existing intraocular lenses have comfort issues after implantation, such as foreign body sensation, glare, and poor stability. Furthermore, adherence to drug treatment and fluctuations in drug concentration affect the vision correction effect.
Design an artificial lens with a bottom-hole-shaped drug-carrying aperture in the optical part to hold the drug, and multiple drug-carrying apertures at the edge of the optical part to increase the drug loading capacity, and achieve slow release of the drug through a sustained-release aperture and a drug reservoir.
It reduces postoperative inflammation, inhibits lens epithelial cell migration, reduces the incidence of posterior capsule opacification, and improves lens stability and visual quality.
Smart Images
Figure CN224584907U_ABST
Abstract
Description
Technical Field
[0001] This utility model relates to the field of biomedical engineering, specifically to an artificial lens. Background Technology
[0002] Cataracts are one of the leading causes of vision impairment worldwide, and surgery is currently the most effective way to restore vision. In cataract surgery, an artificial lens is implanted to replace the original cloudy lens. Figure 1a , Figure 1b An example of a prior art intraocular lens is shown, in which the intraocular lens has an optical portion 1A and a pair of support haptics 2A located on both sides of the optical portion 1A. Furthermore, W in the figure represents the width of the support haptics 2A, and T represents the thickness of the support haptics.
[0003] However, existing intraocular lenses (IOLs) have some shortcomings. Patients also have higher requirements for post-IOL comfort, including reducing foreign body sensation and avoiding glare. Some IOLs have poor stability within the eye and may shift or rotate, affecting visual correction and visual quality. On the other hand, currently, to reduce these complications, postoperative medication such as eye drops is usually used, but this method has problems such as poor patient compliance and large fluctuations in drug concentration. The emergence of drug-eluting IOLs provides a new approach to solving these problems. Therefore, developing an IOL that can alleviate postoperative inflammation has significant clinical importance and market demand. Utility Model Content
[0004] In view of this, the present invention provides an artificial lens that can alleviate postoperative inflammation.
[0005] Therefore, the present invention provides an artificial lens, including an optical part, the optical part having a first drug-carrying hole, the first drug-carrying hole being a bottom hole and opening on one surface of the optical part for containing a drug.
[0006] With the above structure, since the optical part has a first drug-carrying hole, which is a bottomed hole and opens on one surface of the optical part, the relevant drug can be filled in the drug-carrying hole and released through the opening on the surface of the optical part, thereby reducing postoperative inflammation, inhibiting lens epithelial cell migration, and reducing the incidence of posterior capsule opacification.
[0007] In addition, compared with the method of setting drug loading holes on the support haptics, the optical part has a larger area, so it is easier to design drug loading holes and increase the drug loading capacity.
[0008] Alternatively, the first drug-carrying hole is disposed at the edge of the optical part, and a plurality of the first drug-carrying holes are arranged circumferentially along the optical part.
[0009] With the above structure, since the first drug-carrying aperture is located at the edge of the optical part, the interference of the first drug-carrying aperture on human vision can be suppressed.
[0010] Alternatively, the distance between the first drug-carrying hole and the center of the optical part is 5 mm or more or 5.5 ± 1 mm.
[0011] By adopting the above structure, the interference of the first drug-loading aperture on human vision can be suppressed.
[0012] Alternatively, the first drug-carrying aperture has a first aperture portion, which is cylindrical or frustum-shaped with a diameter that gradually increases toward the surface of the optical part.
[0013] By employing a frustum-shaped structure whose diameter gradually increases toward the surface of the optical part, the drug can be stably held and a sustained-release effect can be achieved.
[0014] Alternatively, the diameter of the upper bottom surface of the first hole in the frustum shape is 0.1mm-0.25mm, and the ratio of the diameter of the upper bottom surface to the diameter of the lower bottom surface is 1 / 2-4 / 5.
[0015] Alternatively, the depth of the first hole is 0.2 mm.
[0016] Alternatively, the first aperture may open on one surface of the optical part.
[0017] Alternatively, the first drug-loading aperture has a plurality of sustained-release apertures, which open on one surface of the optical part. The aperture of the sustained-release aperture is smaller than that of the first aperture, and a single first aperture connects to a plurality of the sustained-release apertures.
[0018] Using the above structure, drugs can be released sustainably and exert their effects for a longer period of time.
[0019] Alternatively, the diameter of the slow-release orifice is 0.01mm-0.02mm.
[0020] Alternatively, the diameter of the upper bottom surface of the first hole is 0.1mm-0.2mm, and the diameter of the lower bottom surface is 0.15mm-0.20mm.
[0021] Alternatively, the first drug-loading hole may have a drug storage chamber, which is connected to the first hole.
[0022] Using the above structure can increase drug loading and effectively alleviate postoperative inflammation.
[0023] Alternatively, the capacity of the medicine storage compartment may be greater than that of the first opening.
[0024] Alternatively, the first aperture and the drug reservoir can be configured as a stepped aperture with increasing dimensions towards the optical section.
[0025] Alternatively, the diameter of the drug storage compartment is 0.25mm-0.5mm and the depth is 0.1mm.
[0026] Alternatively, a pair of support haptics connected to the optical unit may be included, wherein the support haptics are provided with a plurality of second drug loading holes, the plurality of second drug loading holes being arranged along the extension direction of the support haptics.
[0027] With the above structure, not only is the first drug loading hole provided on the optical part, but a second drug loading hole is also provided on the support haptic, thereby increasing the drug loading capacity.
[0028] Alternatively, the capacity of the second drug-loading orifice may be smaller than that of the first drug-loading orifice.
[0029] Alternatively, a pair of support loops connected to the optical unit may be included, with a circular buffer ring at the end of each support loop.
[0030] With the above structure, the friction with the pouch can be reduced because a circular buffer ring is provided at the end of the support loop.
[0031] Alternatively, the intraocular lens may also include a pair of support haptics connected to the optical element, wherein the total diameter of the intraocular lens, including the optical element and the support haptics, is 14 mm or more.
[0032] By increasing the total diameter of the intraocular lens (IOL) to 14mm or more, the support haptic can be lengthened, thereby improving the stability and support of the IOL. This optimizes visual quality and prevents IOL tilting or decentering caused by insufficient haptic length, thus reducing higher-order aberrations. Furthermore, it can accommodate different groups, such as those with capsular bag laxity due to trauma or high myopia.
[0033] Alternatively, the diameter of the optical part is 6.0 ± 0.1 mm. Attached Figure Description
[0034] The various technical features of this application and their relationships will be further explained below with reference to the accompanying drawings. The drawings are exemplary; some technical features are not shown to scale, and some drawings may omit technical features commonly used in the art to which this application pertains that are not essential for understanding and implementing this application, or additionally show technical features that are not essential for understanding and implementing this application. In other words, the combination of various technical features shown in the drawings is not intended to limit this application. Furthermore, throughout this application, the same reference numerals refer to the same things. Specific descriptions of the drawings are as follows:
[0035] Figure 1a This is a side view of an existing intraocular lens.
[0036] Figure 1b This is a top view of the aforementioned existing intraocular lens;
[0037] Figure 2 This is a top view schematic diagram of the artificial lens involved in Embodiment 1 of this utility model;
[0038] Figure 3 This is a side view schematic diagram of the intraocular lens of Example 1;
[0039] Figure 4 This is a cross-sectional schematic diagram of the intraocular lens of Example 1;
[0040] Figure 5 yes Figure 4 A partially enlarged view of the cross-section;
[0041] Figure 6 This is a side view schematic diagram of the intraocular lens involved in Example 2;
[0042] Figure 7 This is a top view schematic diagram of the intraocular lens involved in Example 2;
[0043] Figure 8 This is a cross-sectional schematic diagram of the optical part of the intraocular lens involved in Embodiment 3;
[0044] Figure 9 This is a cross-sectional schematic diagram of the intraocular lens involved in Example 4;
[0045] Figure 10 This is a cross-sectional schematic diagram of the optical part of the intraocular lens involved in Embodiment 4;
[0046] Figure 11 This is a partially enlarged schematic diagram of the optical part of the intraocular lens involved in Embodiment 5;
[0047] Figure 12 yes Figure 11 A magnified schematic diagram of the drug-loading orifice in the image;
[0048] Figure 13 This is a partially enlarged cross-sectional view of the optical portion of the intraocular lens involved in Example 5.
[0049] Explanation of reference numerals in the attached figures
[0050] 100 Intraocular lens; 1 Optical section; 10 Drug-loading aperture; 11 Frustum aperture; 12 Drug reservoir; 13 Cylindrical aperture; 14 Sustained-release aperture; 2 Support haptic; 21 Buffer ring; 22 Second drug-loading aperture; 2a Root; 2b Middle; 2c Head. Detailed Implementation
[0051] The specific embodiments of this utility model will now be described in detail with reference to the accompanying drawings.
[0052] This utility model provides an artificial lens 100, such as... Figures 2-13 As shown, the artificial lens 100 has an optical part 1 and a pair of support haptics 2 connected to both sides of the optical part 1. In this embodiment, the support haptics 2 are integrally formed into the optical part.
[0053] Materials used for the artificial lens include, for example, acrylic resin, hydrogel, and silicone. The optical part 1 is roughly circular (when viewed from above, or when viewed along the optical axis of the human eye when worn in the eye), and its diameter can be, for example, 6.0 ± 0.1 mm, with right-angled edges.
[0054] A pair of support loops 2 extend obliquely outward from the outer peripheral edge of the optical part 1, and include a root 2a, a middle part 2b, and a head 2c. In this embodiment, the end of the support loop 2 is formed with a circular buffer ring 21 (when viewed from above). The buffer ring 21 can be integrally formed with the support loop 2 and has a diameter of, for example, 0.68 mm, to reduce pouch friction.
[0055] A plurality of drug-carrying holes 10 are provided on one surface (front surface or rear surface) of the optical part 1. The drug-carrying hole 10 (first drug-carrying hole) is in the shape of a bottom hole and is opened on one surface of the optical part 1 to accommodate drugs.
[0056] The drugs can be, for example, combinations of the following drugs:
[0057] - Anti-inflammatory ingredient: Dexamethasone sodium phosphate (5% w / w).
[0058] - Antiproliferative component: Rapamycin (2% w / w).
[0059] However, it can also be applied to other drugs, or the anti-inflammatory or anti-proliferative components are not limited to the above-mentioned drug examples.
[0060] The following describes a method for loading drugs into the drug loading hole:
[0061] A frustum-shaped drug-carrying hole is machined on the surface using a CNC milling machine. Then, surface treatment is performed: first, a suspension is filled into the drug-carrying hole using a vacuum impregnation method, and after curing, a drug composite layer is formed; subsequently, plasma polishing is performed to remove residual drug from the surface, ensuring that the light transmittance of the optical area is, for example, >98%.
[0062] As an optional method, refer to Figure 2 The drug-carrying holes 10 are provided at the edge of the optical section 1, and a plurality of drug-carrying holes 10 are arranged along the circumference of the optical section 1. Therefore, by providing the drug-carrying holes 10 at the edge of the optical section 1, interference of the drug-carrying holes with human vision can be suppressed.
[0063] Alternatively, the distance between the drug-loading hole 10 and the center of the optical section 1 is 5 mm or more or 5.5 ± 1 mm.
[0064] Alternatively, the drug-loading hole 10 has a frustum-shaped hole 11 as the first hole portion. Figure 4 , Figure 5 (etc.) or cylindrical hole 13 ( Figure 9 , Figure 10 The frustum hole 11 is shaped like a frustum with its diameter gradually increasing towards the surface of the optical part 1, that is, it is small on the outside and large on the inside. In this way, the technical effect of preventing drug detachment or slowing down drug release can be achieved.
[0065] As an option, the diameter D1 of the upper bottom surface of the frustum hole 11 is 0.1mm-0.25mm, and the ratio of the diameter D1 of the upper bottom surface to the diameter D2 of the lower bottom surface is 1 / 2-4 / 5.
[0066] Alternatively, the depth of the frustum hole 11 or the cylindrical hole 13 is 0.2 mm.
[0067] Alternatively, the first aperture is opened on one surface of the optical section.
[0068] As an optional method, such as Figures 11-13 As shown, the drug-carrying hole 10 has a plurality of sustained-release holes 14, which are opened on one surface of the optical part 1. The diameter of the sustained-release hole 14 is smaller than that of the frustum hole 11A, and a single frustum hole 11A connects to the plurality of sustained-release holes 14.
[0069] The diameter of the sustained-release orifice 14 can be 0.01mm-0.02mm. Additionally, the frustum-shaped orifice 11A ( Figure 13 The diameter of the upper base D1 is 0.1mm-0.2mm, and the diameter of the lower base D2 is 0.15mm-0.20mm.
[0070] Alternatively, as an optional method, such as Figures 8-10 As shown, the drug loading hole 10 has a drug storage chamber 12, which is connected to the frustum hole 11 or the cylindrical hole 13.
[0071] The capacity of the drug storage chamber 12 can be greater than that of the frustum hole 11 or the cylindrical hole 13. Specifically, for example, the diameter of the drug storage chamber 12 can be greater than that of the frustum hole 11 or the cylindrical hole 13, so that the frustum hole 11 or the cylindrical hole 13 and the drug storage chamber 12 form a stepped hole shape that increases in size towards the optical part 1.
[0072] The diameter of the medicine storage compartment can be 0.25mm-0.5mm, and the depth can be 0.1mm.
[0073] Alternatively, the support haptic 2 may have multiple drug-carrying holes 22 arranged along the extending direction of the support haptic 2. The capacity of the drug-carrying holes 22 may be smaller than that of the drug-carrying holes 10.
[0074] Alternatively, by increasing the length of the support haptic 12, the total diameter of the intraocular lens 100, including the optical part 1 and the support haptic 2, is 14 mm or more. Furthermore, the diameter of the optical part 1 is 6.0 ± 0.1 mm. Increasing the length of the support haptic 12 improves the stability and support of the intraocular lens 100; it optimizes visual quality, prevents tilting or eccentricity of the intraocular lens 100 due to insufficient haptic length, and thus reduces higher-order aberrations. Additionally, it can accommodate different groups, such as those with capsular bag laxity due to trauma or high myopia.
[0075] The following describes some specific embodiments of this utility model with reference to the accompanying drawings.
[0076] Example 1
[0077] Figure 2 This is a top view schematic diagram of the artificial lens involved in Embodiment 1 of this utility model; Figure 3 This is a side view schematic diagram of the intraocular lens of Example 1; Figure 4 This is a cross-sectional schematic diagram of the intraocular lens of Example 1; Figure 5 yes Figure 4 A magnified view of a section within the image.
[0078] The intraocular lens 100 of this embodiment has an optical section 1 and two support haptics 2. The diameter of the optical section 1 is 6.0 mm. The support haptics 2 are integrally formed with the optical section 1 and are symmetrically distributed 180 degrees on both sides of the optical section 1. The thickness T of the support haptics 2 can be 0.4-0.6 mm, and the length L is set so that the total diameter of the intraocular lens 100 is 14 mm. A circular buffer ring 21 is provided at the end of the support haptics 2 to reduce friction with the capsular bag.
[0079] A plurality of drug-carrying holes 10 (12 in this embodiment) are provided on the optical part 1, located on the outer peripheral edge of the optical part 1, arranged along the circumference of the optical part 1, or arranged around the center of the optical part 1. In this embodiment, the drug-carrying holes 10 are composed of frustum-shaped holes 11, which open on one surface of the optical part 1 and have a shape with a small opening size and a large base size, that is, a shape with a small upper base diameter and a large lower base diameter. In addition, the specific parameters of the frustum-shaped hole 11 can be designed using the following example:
[0080] Example 1: The depth De1 of the frustum hole 11 is 0.2mm, the diameter D1 of the upper base (more precisely, the upper base of the frustum (imaginary)) is 0.10mm, and the diameter D2 of the lower base is as follows:
[0081] ① 0.10mm: 0.125mm ratio 4:5
[0082] ② 0.10mm: 0.15mm ratio 2:3
[0083] ③ 0.10mm: 0.20mm ratio 1:2
[0084] Example 2:
[0085] The depth of the frustum hole 11 is 0.2mm, the diameter of the upper base D1 is 0.25mm, and the diameter of the lower base D2 is as follows:
[0086] ① 0.25mm: 0.312mm ratio 4:5
[0087] ② 0.25mm: 0.375mm ratio 2:3
[0088] ③ 0.25mm: 0.50mm ratio 1:2
[0089] In this embodiment, a drug-carrying hole 10 with a drug coating is provided on the surface of the optical part 1 of the artificial lens 100. Therefore, the drug in the drug-carrying hole 10 can be released into the human eye to suppress inflammation, for example.
[0090] The drug in this embodiment may be, for example, the following combination of drugs:
[0091] - Anti-inflammatory ingredient: Dexamethasone sodium phosphate (5% w / w).
[0092] - Antiproliferative component: Rapamycin (2% w / w).
[0093] This can suppress postoperative inflammation and proliferation.
[0094] Furthermore, compared to the method of providing drug loading holes on the support haptic 2, since the optical part 1 has a larger area, it is easier to design drug loading holes and the drug loading capacity can also be increased.
[0095] In addition, in this embodiment, the overall diameter of the intraocular lens 10 is 14 mm or larger. In the prior art, the overall diameter (including the haptic) of a conventional intraocular lens is typically 13 mm or smaller. In this embodiment, the supporting haptic 2 of the intraocular lens is lengthened, resulting in an overall diameter of 14 mm. The longer haptic improves the stability and support of the lens; it optimizes visual quality and avoids lens tilting or eccentricity caused by insufficient haptic length, thereby reducing higher-order aberrations. It can also accommodate different groups, such as those with capsular bag laxity due to trauma or high myopia.
[0096] Example 2
[0097] Figure 6 This is a side view schematic diagram of the intraocular lens involved in Example 2; Figure 7 This is a top view schematic diagram of the intraocular lens involved in Example 2; Figure 8 This is a cross-sectional schematic diagram of the optical part of the intraocular lens involved in Embodiment 2.
[0098] The difference between Embodiment 2 and Embodiment 1 is that each of the two support haptics 2 has four drug-carrying holes 22 with drug coatings. The other structures are the same as those in the above embodiments, so the same reference numerals are used and detailed descriptions are omitted.
[0099] Compared with the previous embodiment, this embodiment has a higher drug loading capacity, and the support loop 2 can also inhibit the migration of lens epithelial cells and reduce the incidence of posterior capsule opacification.
[0100] In addition, such as Figure 7 As shown, the capacity of the drug-carrying hole 22 can be smaller than that of the drug-carrying hole 10. For example, the diameter of the drug-carrying hole 22 is smaller than the diameter D1 of the upper bottom surface of the frustum hole 11 of the drug-carrying hole 10.
[0101] Example 3
[0102] Figure 8 This is a cross-sectional schematic diagram of the optical part of the artificial lens involved in Embodiment 3.
[0103] The difference between this embodiment and the above embodiments is that, in this embodiment, the drug-carrying hole 10 also has a drug storage chamber 12. The drug storage chamber 12 is located inside the frustum hole 11, communicates with the frustum hole 11, and has a diameter larger than the frustum hole 11, forming a stepped hole shape with the diameter increasing towards the inner side. Other structures are the same as in the above embodiments, and detailed descriptions are omitted here.
[0104] In this embodiment, the diameter D1 of the upper bottom surface of the frustum hole 11 is 0.10-0.20mm, the diameter D2 of the lower bottom surface is 0.15-0.20mm, the diameter D3 of the internal drug storage chamber 12 is 0.25-0.50mm, the depth De2 is 0.10mm, and the overall depth De3 of the frustum hole 11 + drug storage chamber 12, or the depth of the drug loading hole 10, is 0.2mm.
[0105] Compared with the above embodiments, this embodiment adds an internal drug storage compartment 12, which can store more drugs, effectively reduce postoperative inflammation, inhibit lens epithelial cell migration, and reduce the incidence of posterior capsule opacification.
[0106] Example 4
[0107] Figure 9 This is a cross-sectional schematic diagram of the intraocular lens involved in Example 4; Figure 10 This is a cross-sectional schematic diagram of the optical part of the artificial lens involved in Embodiment 4.
[0108] and Figure 8 The difference in the illustrated embodiment is that a cylindrical hole 13 is used instead of the shown hole in this embodiment. Figure 8 The frustum-shaped hole 11 in the middle.
[0109] The diameter D4 of the cylindrical hole 13 is 0.2 mm, and the depth is 0.1 mm. The dimensions of the drug storage chamber 12 are the same as in the above embodiment. In addition, the overall depth De4 of the cylindrical hole 13 and the drug storage chamber 12 is 0.2 mm.
[0110] Example 5
[0111] Figure 11 This is a partially enlarged schematic diagram of the optical part of the intraocular lens involved in Embodiment 5; Figure 12 yes Figure 11 A magnified schematic diagram of the drug-loading orifice in the image; Figure 13 This is a partially enlarged cross-sectional view of the optical portion of the intraocular lens involved in Example 5.
[0112] This embodiment and Figure 8 The difference in the illustrated embodiment is that the frustum-shaped aperture 11A is not open on the surface of the optical part 1, but rather communicates with a plurality of sustained-release holes 14 formed on the surface of the optical part 1, connecting to the outside world through the sustained-release holes 14 to release the drug. These sustained-release holes 14 can be arranged in an array. Figures 11-13 In the example, there are 12 slow-release wells arranged in a 3*4 matrix.
[0113] The parameters for these holes are as follows:
[0114] The diameter D1 of the upper bottom surface of the frustum hole 11A is 0.10-0.20 mm.
[0115] The diameter D2 of the lower base of the frustum hole 11A is 0.15-0.20 mm.
[0116] The pore size D5 of the sustained-release pore 14 is 0.01-0.02 mm.
[0117] The diameter D3 of the medicine storage compartment 12 is 0.25-0.50 mm and the depth is 0.10 mm.
[0118] The overall depth of De5 is 0.2mm.
[0119] In this embodiment, the presence of the sustained-release orifice 14 allows for a longer drug release time, effectively reducing postoperative inflammation, inhibiting lens epithelial cell migration, and lowering the incidence of posterior capsule opacification.
[0120] Note that the above are merely preferred embodiments and the technical principles employed in this application. Those skilled in the art will understand that this application is not limited to the specific embodiments described herein, and various obvious changes, readjustments, and substitutions can be made without departing from the scope of protection of this application. Therefore, although this application has been described in detail through the above embodiments, this application is not limited to the above embodiments. Many other equivalent embodiments may be included without departing from the technical concept of this application, all of which fall within the scope of protection of this application.
Claims
1. An intraocular lens comprising an optical portion, characterized in that, The optical part has a first drug-carrying hole, which is a bottomed hole that opens on one surface of the optical part to accommodate a drug.
2. The intraocular lens of claim 1, wherein The first drug-carrying hole is disposed at the edge of the optical part, and a plurality of the first drug-carrying holes are arranged along the circumference of the optical part.
3. The intraocular lens of claim 1, wherein, The distance between the first drug-carrying hole and the center of the optical part is 5 mm or more or 5.5 ± 1 mm.
4. The intraocular lens of claim 1, wherein, The first drug-carrying aperture has a first aperture portion, which is cylindrical or frustum-shaped with a diameter that gradually increases toward the surface of the optical part.
5. The intraocular lens of claim 4, wherein, The diameter of the upper base of the first hole, which is truncated cone-shaped, is 0.1mm-0.25mm, and the ratio of the upper base diameter to the lower base diameter is 1 / 2-4 / 5. The depth of the first hole is 0.2 mm. The first aperture opens on one surface of the optical part.
6. The intraocular lens of claim 4, wherein, The first drug-loading aperture has multiple sustained-release apertures, which open on one surface of the optical part. The aperture of each sustained-release aperture is smaller than that of the first aperture, and a single first aperture connects to multiple sustained-release apertures.
7. The intraocular lens of claim 6, wherein, The diameter of the slow-release pore is 0.01mm-0.02mm. The diameter of the upper bottom surface of the first hole is 0.1mm-0.2mm, and the diameter of the lower bottom surface is 0.15mm-0.20mm.
8. The intraocular lens according to any one of claims 4 to 7, characterized in that The first drug loading hole has a drug storage chamber, which is connected to the first hole.
9. The intraocular lens of claim 8, wherein, The capacity of the medicine storage compartment is greater than that of the first opening.
10. The intraocular lens of claim 8, wherein, The first aperture and the drug storage chamber form a stepped aperture shape that increases in size towards the optical part. The diameter of the drug storage compartment is 0.25mm-0.5mm, and the depth is 0.1mm.
11. The intraocular lens of any of claims 1-7, wherein, It also includes a pair of support loops connected to the optical unit, on which a plurality of second drug loading holes are provided, and the plurality of second drug loading holes are arranged along the extension direction of the support loops.
12. The intraocular lens of claim 11, wherein, The capacity of the second drug-loading orifice is smaller than that of the first drug-loading orifice.
13. The intraocular lens of any of claims 1-7, wherein, It also includes a pair of support loops connected to the optical part, with a circular buffer ring at the end of the support loops.